Synthesis and stereochemical effects of pyrrolidinyl-acetylenic thieno[3,2- d]pyrimidines as EGFR and ErbB-2 inhibitors

Autor: Stevens, Kirk L., Alligood, Krystal J., Alberti, Jennifer G. Badiang, Caferro, Thomas R., Chamberlain, Stanley D., Dickerson, Scott H., Dickson, Hamilton D., Emerson, Holly K., Griffin, Robert J., Hubbard, Robert D., Keith, Barry R., Mullin, Robert J., Petrov, Kimberly G., Gerding, Roseanne M., Reno, Michael J., Rheault, Tara R., Rusnak, David W., Sammond, Douglas M., Smith, Stephon C., Uehling, David E., Waterson, Alex G., Wood, Edgar R.

Publikováno v: In Bioorganic & Medicinal Chemistry Letters 2009 19(1):21-26

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.

Autor: Wenle Xia, Mullin, Robert J., Keith, Barry R., Lei-Hua Liu, Hong Ma, Rusnak, David W., Owens, Gary, Alligood, Krystal J., Spector, Neil L.

Publikováno v: Oncogene; 9/12/2002, Vol. 21 Issue 41, p6255, 9p, 6 Black and White Photographs, 1 Graph

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.

Autor: Konecny GE; Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, 12-145 Factor Building, 10945 Le Conte Avenue, Los Angeles, CA 90095-1678, USA. gkonecny@ucla.edu, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ

Publikováno v: Cancer research [Cancer Res] 2006 Feb 01; Vol. 66 (3), pp. 1630-9.